Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DLBS1033 for Acute Ischemic Stroke Patients (ADDLIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02133521
Recruitment Status : Recruiting
First Posted : May 8, 2014
Last Update Posted : January 7, 2021
Sponsor:
Information provided by (Responsible Party):
Dexa Medica Group

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a prospective, randomized, double-blind, and controlled clinical study to investigate the effects of DLBS1033 in conjunction with standard therapy compared to standard therapy alone in acute ischemic stroke patients. It is hypothesized that the improvement in functional outcomes as measured by NIHSS and BI as well as the improvement in haemostatic parameters as measured by thrombocyte aggregation test (TAT), fibrinogen, and d-dimer in DLBS group will be significantly greater than those in the control group.

Condition or disease Intervention/treatment Phase
Acute Ischemic Stroke Partial Anterior Circulation Infarct Lacunar Anterior Circulation Infarct Drug: DLBS1033 Drug: Placebo Phase 2 Phase 3

Detailed Description:

Subjects in this study will be screened consecutively and eligible subjects will be randomized into two groups and receive the investigational drug, DLBS1033 at a dose of 490 mg three times daily or its placebo in addition to standard therapy for 28-days course of therapy. Standard therapy used in this study will consist of: aspirin 80 mg, simvastatin 20 mg, and vitamin B complex.

After hospital admission and diagnosis, patient will be handled as per acute ischemic stroke management in each study site. Right after the patient is confirmed eligible to the study, the treatment(s) will be switched immediately into the study treatments. Clinical and laboratory examinations to evaluate the investigational drug's efficacy will be performed at baseline and 3, 7,14, and 28 days after study medication initiation; while safety examinations will be performed at the same time point, but 3 and 14 days after study medication initiation.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Addition of DLBS1033 to Standard Therapy for Acute Ischemic Stroke Patients
Study Start Date : October 2014
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : September 2023
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo 3 x 1 tablet, given everyday for 28 days of study period
 Drug: Placebo
Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
Experimental: DLBS1033
DLBS1033 enteric-coated tablet 3 x 490 mg daily, given everyday for 28 days of study period
 Drug: DLBS1033
Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
Other Name: Disolf


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. National Institutes of Health Stroke Scale (NIHSS) [ Time Frame: 3, 7, 14, and 28 days after study medication ]
    Change in functional outcomes as measured by NIHSS from its baseline value

  2. Barthel Index (BI) [ Time Frame: 3, 7, 14, and 28 days after study medication ]
    Change in functional outcomes as measured by BI from its baseline value


Secondary Outcome Measures :
  1. Thrombocyte Aggregation Test (TAT) [ Time Frame: 3, 7, 14, and 28 days after study medication ]
    Change in haemostatic parameter as measured by TAT from its baseline value

  2. Fibrinogen level [ Time Frame: 3, 7, 14, and 28 days after study medication ]
    Change in haemostatic parameter as measured by fibrinogen level from its baseline value

  3. D-dimer level [ Time Frame: 3, 7, 14, and 28 days after study medication ]
    Change in haemostatic parameter as measured by d-dimer level from its baseline value

  4. Liver function [ Time Frame: 7 and 28 days after study medication ]
    Liver function measured includes: serum AST, ALT, gamma-GT, total bilirubin

  5. Renal function [ Time Frame: 7 and 28 days after study medication ]
    Renal function measured includes: serum creatinine

  6. Routine hematology [ Time Frame: 7 and 28 days after study medication ]
    Routine hematology measured includes: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count

  7. Adverse events [ Time Frame: 1 - 28 days ]
    Adverse events, including bleeding events, will be observed and carefully evaluated along the course of the study


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent from the patients or patients' legally acceptable representatives (must be obtained before any trial related activities).
  • Male or female subjects with age of >18 years at Screening.
  • Patients clinically diagnosed having acute ischemic stroke attack and confirmed by CT scan.
  • Patients with cerebral infarction subtypes of PACI or LACI as classified by Bamford criteria.
  • Patients with moderate condition based on National Institutes of Health Stroke Scale (NIHSS) score of 5-15.
  • Patients present at hospital and receiving first dose of study medication within 72 hours after the onset of the stroke symptoms.
  • Able to take oral medication.

Exclusion Criteria:

  • For females of childbearing potential: pregnancy and lactation period.
  • History of hemorrhagic stroke within the last 3 months.
  • Patients with seizure at the onset of stroke or with regular medication for seizure/epilepsy.
  • Current or regular use (within the last 1 month) of oral anticoagulants, antiplatelets other than study medication, and herbal medicines.
  • Patients who have received tissue plasminogen activator (TPA) within 24 hours to Screening.
  • History of serious head injury within the last 3 months.
  • History of major surgery within the last 3 months.
  • Recent serious cardiovascular conditions, such as myocardial infarction and heart atrial fibrillation as demonstrated by electrocardiography (ECG).
  • History of congestive heart failure and aortic dissection.
  • Presence of severe renal and hepatic dysfunction, defined as serum creatinine level > 3x upper limit of normal (ULN) or history of hemodialysis, and any of serum ALT, AST, Gamma-GT level of > 3x ULN, respectively.
  • Presence of acute SIRS.
  • Presence of chronic infections.
  • Patients with higher risks of bleeding.
  • Subjects with uncontrolled hypertension (systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg).
  • Subjects with random plasma glucose ≥180 mg/dL and HbA1c ≥ 7.0% at Screening.
  • Known or suspected hypersensitivity to the trial product or related products.
  • Participation in any other clinical studies within 30 days prior to screening.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02133521


Contacts
Layout table for location contacts
Contact: Paulus Sugianto, Sp.S(K), Dr, MD paulus.sugianto@gmail.com
Contact: Hasan Machfoed, Prof., Sp.S(K), MD mh.machfoed@gmail.com

Locations
Layout table for location information
Indonesia
Neurology Department, Dr. Kariadi General Hospital Completed
Semarang, Central Java, Indonesia
Neurology Department Islam Jakarta Hospital (RSIJ) Cempaka Putih Not yet recruiting
Jakarta Pusat, DKI Jakarta, Indonesia
Contact: Wiwin Sundawiyani, Sp.S, MD    +6281383144399      
Principal Investigator: Wiwin Sundawiyani, Sp.S, MD         
Sub-Investigator: Taufik Mesiano, Sp.S, MD         
Sub-Investigator: Elfa A Ersyanti, Sp.N, MD         
Neurology Department Fatmawati Regional General Hospital Not yet recruiting
Jakarta, DKI Jakarta, Indonesia
Contact: Ika Y Margaretha, Sp.S, MD    +62852256654666      
Principal Investigator: Ika Y Margaretha, Sp.S, MD         
Sub-Investigator: Susi Harini, Sp.S, MD         
Sub-Investigator: Hastari Sukardi, Sp.S, MD         
Sub-Investigator: Arfan Mappalilu, Sp.S, MD         
Sub-Investigator: Fritz Sumantri, Sp.S, MD         
Sub-Investigator: Maysam Irawati, Sp.S, MD         
Sub-Investigator: Yuniarti Yuniarti, Sp.S, MD         
Sub-Investigator: Fitriany Nasution, Sp.S, MD         
Neurology Department, Budhi Asih Hospital Not yet recruiting
Jakarta, DKI Jakarta, Indonesia
Contact: Dian Cahyani, MD., SpS    +6212 1064 031      
Principal Investigator: Dian Cahyani, MD., SpS         
Sub-Investigator: Ananda Setiabudi, MD., SpS         
Sub-Investigator: Julintari Indiyani, MD., SpS         
Neurology Department, Pasar Rebo Hospital Recruiting
Jakarta, DKI Jakarta, Indonesia
Contact: Gotot S PW, Sp. S, MD    +621 8400 109      
Principal Investigator: Gotot S PW, Sp. S, MD         
Sub-Investigator: Ridwan Ridwan, Sp. S, MD         
Sub-Investigator: Donny H Hamid, Sp. S, MD         
Neurology Department Sidoarjo Regional General Hospital Not yet recruiting
Sidoarjo, East Java, Indonesia
Contact: Sugeng Wijayanto, Sp.S, MD    +62812 5940 4413      
Principal Investigator: Sugeng Wijayanto, Sp.S, MD         
Sub-Investigator: Hanifah H W, Sp.S, MD         
Sub-Investigator: Andiva S R, Sp.S, MD         
Neurology Department, Haji Surabaya Hospital Completed
Surabaya, East Java, Indonesia
Stroke/Cerebrobascular Division, Neurology Department, Dr. Soetomo Hospital Completed
Surabaya, East Java, Indonesia
Sponsors and Collaborators
Dexa Medica Group
Investigators
Layout table for investigator information
Study Director: Hasan Machfoed, Prof, Sp.S(K), MD Neurology Department Dr. Soetomo Hospital
Study Chair: Paulus Sugianto, Sp.S(K), Dr, MD Indonesia's Neurologists Organization (Perdossi)
Principal Investigator: Muh. Hamdan, Sp.S(K), MD Neurology Department Dr. Soetomo Hospital
Principal Investigator: Dodik Tugasworo, Sp.S(K), MD Neurology Department Dr. Kariadi General Hospital
Principal Investigator: Dian Cahyani, Sp.S, MD Neurology Department Budhi Asih Hospital
Principal Investigator: Diah H Soeryaningtias, Sp.S, MD Neurology Department Haji Surabaya Hospital
Principal Investigator: Gotot S PW, Sp.S, MD Neurology Department Pasar Rebo Hospital
Principal Investigator: Sugeng Wijayanto, Sp.S, MD Neurology Department Sidoarjo Regional General Hospital
Principal Investigator: Ika Y Margaretha, Sp.S, MD Neurology Department Fatmawati Regional General Hospital
Principal Investigator: Wiwin Sundawiyani, Sp.S, MD Islam Jakarta Hospital (RSIJ) Cempaka Putih
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Dexa Medica Group
ClinicalTrials.gov Identifier: NCT02133521    
Other Study ID Numbers: DLBS1033-0111
First Posted: May 8, 2014    Key Record Dates
Last Update Posted: January 7, 2021
Last Verified: January 2021
Keywords provided by Dexa Medica Group:
DLBS1033
Acute ischemic stroke
NIHSS
Barthel Index
Additional relevant MeSH terms:
Layout table for MeSH terms
Stroke
Cerebral Infarction
Ischemia
Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Pathologic Processes
Brain Infarction
Brain Ischemia
Necrosis